Latest Insider Transactions at Becton Dickinson & CO (BDX)
This section provides a real-time view of insider transactions for Becton Dickinson & CO (BDX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BECTON DICKINSON & CO to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BECTON DICKINSON & CO's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 01
2023
|
Michelle Quinn EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-2.93%
|
-
|
|
Apr 04
2023
|
Shana Carol Neal EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,229
+32.74%
|
-
|
|
Apr 04
2023
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
731
-7.77%
|
-
|
|
Mar 02
2023
|
Antoine C Ezell EVP, President Americas & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
650
-8.29%
|
-
|
|
Mar 01
2023
|
Antoine C Ezell EVP, President Americas & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
418
-5.06%
|
-
|
|
Mar 01
2023
|
Michael David Garrison EVP & President, Medical |
SELL
Payment of exercise price or tax liability
|
Direct |
193
-2.9%
|
-
|
|
Mar 01
2023
|
Thomas J Spoerel SVPController & Chief Acct Off |
SELL
Payment of exercise price or tax liability
|
Direct |
35
-1.83%
|
-
|
|
Feb 03
2023
|
Richard Byrd EVP & President Interventional |
SELL
Open market or private sale
|
Direct |
1,421
-25.65%
|
$352,408
$248.6 P/Share
|
|
Jan 26
2023
|
Claire Fraser Director |
BUY
Grant, award, or other acquisition
|
Direct |
848
+3.66%
|
-
|
|
Jan 24
2023
|
Timothy M Ring Director |
BUY
Grant, award, or other acquisition
|
Direct |
848
+1.06%
|
-
|
|
Jan 24
2023
|
Bertram L Scott Director |
BUY
Grant, award, or other acquisition
|
Direct |
848
+2.45%
|
-
|
|
Jan 24
2023
|
Jeffrey William Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
848
+15.42%
|
-
|
|
Jan 24
2023
|
Christopher Ian Montague Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
848
+2.82%
|
-
|
|
Jan 24
2023
|
Marshall O Larsen Director |
BUY
Grant, award, or other acquisition
|
Direct |
848
+2.85%
|
-
|
|
Jan 24
2023
|
William M Brown Director |
BUY
Grant, award, or other acquisition
|
Direct |
848
+34.84%
|
-
|
|
Jan 24
2023
|
Carrie L Byington Director |
BUY
Grant, award, or other acquisition
|
Direct |
848
+30.59%
|
-
|
|
Jan 24
2023
|
Catherine M Burzik Director |
BUY
Grant, award, or other acquisition
|
Direct |
848
+5.94%
|
-
|
|
Jan 24
2023
|
R Andrew Eckert Director |
BUY
Grant, award, or other acquisition
|
Direct |
848
+10.82%
|
-
|
|
Dec 21
2022
|
Samrat S. Khichi EVP and General Counsel |
SELL
Bona fide gift
|
Direct |
19
-0.21%
|
-
|
|
Dec 13
2022
|
Samrat S. Khichi EVP and General Counsel |
SELL
Bona fide gift
|
Direct |
40
-0.43%
|
-
|
|
Nov 26
2022
|
Thomas E Polen Jr Chairman, CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
30,047
-19.72%
|
-
|
|
Nov 26
2022
|
Thomas E Polen Jr Chairman, CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
72,980
+21.97%
|
-
|
|
Nov 26
2022
|
Thomas J Spoerel SVPController & Chief Acct Off |
SELL
Payment of exercise price or tax liability
|
Direct |
232
-10.84%
|
-
|
|
Nov 26
2022
|
Thomas J Spoerel SVPController & Chief Acct Off |
BUY
Grant, award, or other acquisition
|
Direct |
669
+14.48%
|
-
|
|
Nov 26
2022
|
Samrat S. Khichi EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,908
-17.01%
|
-
|
|
Nov 26
2022
|
Samrat S. Khichi EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
5,290
+20.66%
|
-
|
|
Nov 26
2022
|
Roland Goette EVP and President, EMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-0.72%
|
-
|
|
Nov 26
2022
|
Roland Goette EVP and President, EMEA |
BUY
Grant, award, or other acquisition
|
Direct |
1,819
+6.38%
|
-
|
|
Nov 26
2022
|
Pavan Kumar Mocherla EVP & President Greater Asia |
SELL
Payment of exercise price or tax liability
|
Direct |
46
-3.91%
|
-
|
|
Nov 26
2022
|
Pavan Kumar Mocherla EVP & President Greater Asia |
BUY
Grant, award, or other acquisition
|
Direct |
462
+16.47%
|
-
|
|
Nov 26
2022
|
David Hickey EVP & President, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
1,816
+26.08%
|
-
|
|
Nov 26
2022
|
Christopher Del Orefice EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
269
-2.2%
|
-
|
|
Nov 26
2022
|
Christopher Del Orefice EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,087
+20.16%
|
-
|
|
Nov 26
2022
|
Antoine C Ezell EVP, President Americas & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
115
-1.37%
|
-
|
|
Nov 26
2022
|
Antoine C Ezell EVP, President Americas & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
1,045
+11.1%
|
-
|
|
Nov 26
2022
|
Shana Carol Neal EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,812
+16.15%
|
-
|
|
Nov 26
2022
|
Richard Byrd EVP & President Interventional |
SELL
Payment of exercise price or tax liability
|
Direct |
711
-11.37%
|
-
|
|
Nov 26
2022
|
Richard Byrd EVP & President Interventional |
BUY
Grant, award, or other acquisition
|
Direct |
2,501
+18.35%
|
-
|
|
Nov 26
2022
|
Michael David Garrison EVP & President, Medical |
SELL
Payment of exercise price or tax liability
|
Direct |
617
-8.49%
|
-
|
|
Nov 26
2022
|
Michael David Garrison EVP & President, Medical |
BUY
Grant, award, or other acquisition
|
Direct |
2,790
+17.5%
|
-
|
|
Nov 18
2022
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
31
-0.18%
|
-
|
|
Nov 18
2022
|
Shana Carol Neal EVP and Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
110
+0.65%
|
-
|
|
Nov 16
2022
|
Roland Goette EVP and President, EMEA |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,996
-20.11%
|
$665,112
$222.08 P/Share
|
|
Nov 16
2022
|
Roland Goette EVP and President, EMEA |
BUY
Exercise of conversion of derivative security
|
Direct |
4,617
+23.66%
|
$341,658
$74.94 P/Share
|
|
Sep 07
2022
|
Christopher Del Orefice EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
506
-5.25%
|
-
|
|
Sep 01
2022
|
Christopher Del Orefice EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,674
+21.71%
|
-
|
|
Aug 15
2022
|
Thomas E Polen Jr Chairman, CEO and President |
SELL
Open market or private sale
|
Direct |
9,500
-24.75%
|
$2,517,500
$265.13 P/Share
|
|
Aug 15
2022
|
Thomas E Polen Jr Chairman, CEO and President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,500
-12.53%
|
$1,457,500
$265.13 P/Share
|
|
Aug 15
2022
|
Thomas E Polen Jr Chairman, CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+25.48%
|
$2,505,000
$167.91 P/Share
|
|
Aug 15
2022
|
David Hickey EVP & President, Life Sciences |
SELL
Open market or private sale
|
Direct |
475
-12.48%
|
$125,875
$265.0 P/Share
|